Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Eclinicalmedicine|April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentLuca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Zijun Y Xu-Monette, Xin Cao, et al.
Lancet (London, England)|May 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL NetworkMartin Dreyling, Jeanette Doorduijn, Eva Giné, et al.
American Journal of Hematology|April 16, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International ExperienceBruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Cancer Immunology Research|February 13, 2019
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCLZiju Y Xu-Monette, Min Xiao, Qingyan Au, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Neoplasia (New York, N.Y.)|May 8, 2018
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell LymphomaXiaoxiao Wang, Xin Cao, Ruifang Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.
Pageof 19